CSC
CLDX icon

Caldwell Sutter Capital’s Celldex Therapeutics CLDX Stock Holding History

Caldwell Sutter Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-350
Closed -$6.35K – 866
2025
Q1 		$6.35K Hold
350
– – ﹤0.01% 597
2024
Q4 		$8.85K Hold
350
– – ﹤0.01% 567
2024
Q3 		$11.9K Hold
350
– – 0.01% 541
2024
Q2 		$13K Hold
350
– – 0.01% 529
2024
Q1 		$14.7K Hold
350
– – 0.01% 504
2023
Q4 		$13.9K Hold
350
– – 0.01% 505
2023
Q3 		$9.63K Hold
350
– – 0.01% 536
2023
Q2 		$11.9K Hold
350
– – 0.01% 506
2023
Q1 		$12.6K Hold
350
– – 0.01% 381
2022
Q4 		$15.6K Buy
+350
New +$12.5K 0.01% 237

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caldwell Sutter Capital's CLDX Position: Q2 2025 in Review

Caldwell Sutter Capital sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 350 shares — an estimated $6.35K sold.

Caldwell Sutter Capital first reported a position in CLDX in Q4 2022 and held it in 10 quarters. The position peaked at $15.6K in Q4 2022. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Caldwell Sutter Capital reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caldwell Sutter Capital sold 350 Celldex Therapeutics shares in Q2 2025, an estimated $6.35K.
  • Caldwell Sutter Capital first reported a position in Celldex Therapeutics in Q4 2022 and held it in 10 quarters.
  • Caldwell Sutter Capital's Celldex Therapeutics position peaked at $15.6K in Q4 2022.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Caldwell Sutter Capital's 13F filing for Q2 2025, filed 11 Jul 2025.